Beyond Air Inc XAIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
-
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
-
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
-
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
-
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
-
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
-
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
Trading Information
- Previous Close Price
- $2.21
- Day Range
- $2.22–2.27
- 52-Week Range
- $2.05–53.20
- Bid/Ask
- $2.19 / $2.26
- Shares Outstanding
- 984,407.00
- Market Cap
- $2.21M
- Volume/Avg
- 8,706 / 216,802
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 54
- Website
- https://www.beyondair.net
Valuation
|
Metric
|
XAIR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.82 |
Price/Sales | 0.15 |
Price/Cash Flow | — |
Price/Earnings
XAIR
Financial Strength
|
Metric
|
XAIR
|
|---|---|
Quick Ratio | 1.60 |
Current Ratio | 3.31 |
Interest Coverage | −6.72 |
Quick Ratio
XAIR
Profitability
|
Metric
|
XAIR
|
|---|---|
Return on Assets (Normalized) | −83.71% |
Return on Equity (Normalized) | −353.27% |
Return on Invested Capital (Normalized) | −84.17% |
Return on Assets
XAIR
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|@y$$^B% | LOCK|P?G$> | $181B | |||
| Medtronic PLC
MDT
| LOCK|#w&p$@> | LOCK|mq@! | $122B | |||
| Stryker Corp
SYK
| LOCK|H@$PQhVs | LOCK|^g | $112B | |||
| Boston Scientific Corp
BSX
| LOCK|q<%$cH | LOCK|VMG$@ | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|RD!YdF! | LOCK|#qmr | $51B | |||
| DexCom Inc
DXCM
| LOCK|rtQB%N@B | LOCK|N^xk# | $33B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|Fw^!&QH | LOCK|Ym | $32B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|Wn | LOCK|#P! | $25B | |||
| Steris PLC
STE
| LOCK|f>X&xcX | LOCK|#R?dc | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|^@cSb<r# | LOCK|JH# | $18B |
United States